Blood Cytokines as Biomarkers of In Vivo Toxicity in Preclinical Safety Assessment: Considerations for Their Use
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
In the drive to develop drugs with well-characterized and clinically monitorable safety profiles, there is incentive to expand the repertoire of safety biomarkers for toxicities without routine markers or premonitory detection. Biomarkers in blood are pursued because of specimen accessibility, opportunity for serial monitoring, quantitative measurement, and the availability of assay platforms. Cytokines, chemokines, and growth factors (here referred to collectively as cytokines) show robust modulation in proximal events of inflammation, immune response, and repair. These are key general processes in many toxicities; therefore, cytokines are commonly identified during biomarker discovery studies. In addition, multiplexed cytokine immunoassays are easily applied to biomarker discovery and routine toxicity studies to measure blood cytokines. However, cytokines pose several challenges as safety biomarkers because of a short serum half-life; low to undetectable baseline levels; lack of tissue-specific or toxicity-specific expression; complexities related to cytokine expression with multiorgan involvement; and species, strain, and interindividual differences. Additional challenges to their application are caused by analytical, methodological, and study design-related variables. A final consideration is the strength of the relationship between changes in cytokine levels and the development of phenotypic or functional manifestations of toxicity. These factors should inform the integrated judgment-based qualification of novel biomarkers in preclinical, and potentially clinical, risk assessment. The dearth of robust, predictive cytokine biomarkers for specific toxicities is an indication of the significant complexity of these challenges. This review will consider the current state of the science and recommendations for appropriate application of cytokines in preclinical safety assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 3×
“Prominent examples of such physiological roles include maintenance of vascular integrity, the interplay of energy metabolism with the immune system, and neurohumoral stress (Medzhitov, 2008).”
BackgroundInfluentialOf Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 2×
“Thus, a minimal expectation for the use of cytokines as safety biomarkers is that they are specific, sensitive, and show reliable temporal kinetics that permit detection, persistence, and resolution of toxicity.”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 2×
“Cynomologous macaques did not predict the exaggerated immune stimulation (cytokine storm) experienced in the phase I clinical trial (Suntharalingam et al., 2006).”
BackgroundThe Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146 · cited 17×
“T-lymphocyte cytokines divine the Th1 (interferon gamma, IFNc, and interleukin 12, IL12), Th2 (IL4, IL5, IL6, and IL13), Th17 (IL17, IL21, and IL22), and T-regulatory (transforming growth factor beta, TGFb, and IL10) subsets of T cells that stimulate or modulate the adaptive immune response to infectious agents and ot…”
BackgroundInfluentialTranscriptional control of the inflammatory response
Medzhitov, R., & Horng, T. (2009) · Nature Reviews Immunology · doi:10.1038/nri2634 · Cited by 1,035
A circadian clock in macrophages controls inflammatory immune responses
Keller, M., Mazuch, J., Abraham, U., Eom, G. D., Herzog, E. D., Volk, H.-D., Kramer, A., & Maier, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906361106 · Cited by 843 · cited 1×
“Fascinating is the recent work that establishes the presence of local and cell-autonomous circadian rhythms in lymphoid organs and peritoneal macrophages (Keller et al., 2009).”
BackgroundCytokine and cytokine receptor gene polymorphisms and their functionality
Smith, A. J. P., & Humphries, S. E. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.006 · Cited by 374 · cited 1×
“Functional single nucleotide polymorphisms of cytokine genes in the human population can result in different levels of expression in healthy individuals and have disease associations with autoimmunity, susceptibility to infection, cardiovascular disease, and cancer (Smith and Humphries, 2009).”
BackgroundForecasting the cytokine storm following systemic interleukin (IL)-2 administration
Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-17 · Cited by 139 · cited 2×
“In addition, bioinformatics techniques such as principal component analysis (Wong et al., 2008) and hierarchical cluster analysis (Khan et al., 2009; Panelli et al., 2004) can be used to detect relationships between multiple analytes and between specimens.”
BackgroundMethodA CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46 · cited 3×
“A surrogate anti-rat-CD28 antibody (JJ316) also failed to elicit a cytokine storm in the rat (Muller et al., 2008).”
Background
Cited by
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C. I., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 521
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19486-2 · Cited by 446
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570340 · Cited by 35
“Tarrant, J. M. (2010). Blood cytokines as biomarkers of in vivo toxicity in”
BackgroundMaiti, A. K., Sharba, S., Navabi, N., Forsman, H., Fernandez, H. R., & Lindén, S. K. (2015) · Scientific Reports · doi:10.1038/srep15434 · Cited by 25
Metadata
- Authors
- Tarrant, J. M.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-06
- Volume
- 117
- Issue
- 1
- Pages
- 4-16
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2143509389
- Cited by
- 141
- References
- 9
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.